Overview of bladder cancer trials in the
โ
Eric J. Small; Susan Halabi; Guido Dalbagni; Raj Pruthi; George Phillips; Martin
๐
Article
๐
2003
๐
John Wiley and Sons
๐
English
โ 110 KB
๐ 1 views
The Cancer and Leukemia Group B (CALGB) Genitourinary Committee has developed a broad range of clinical trials across most stages of bladder cancer. Recurrence rates of superficial bladder cancer after transurethral resection range from 50-70%. Although adjuvant bacillus Calmette-Guerin reduces the